A Phase II Study of BEZ235 in Patients with Everolimus- resistant, Advanced Pancreatic Neuroendocrine Tumours

Hubner, Richard A.; Lahner, H.; Raderer, M.; Buzzoni, R.; Teulé, A.; Baudin, E.; Fazio, Nicola; Libutti, Sk; Antonuzzo, L.; Kulke, Mh; Shah, M.; De Herder, Ww; Turri, S.; Capdevila, J.; Massacesi, C.; Verslype, C.; Dey, D.; Aimone, P.

Links

ORCID
[hdl.handle.net]
[www.researchgate.net] | PDF

Tools

Export citation

Search in Google Scholar

A Phase II Study of BEZ235 in Patients with Everolimus- resistant, Advanced Pancreatic Neuroendocrine Tumours

Journal article published in 2016 by Richard A. Hubner, H. Lahner, M. Raderer, R. Buzzoni, A. Teulé, E. Baudin, Nicola Fazio, Sk Libutti, L. Antonuzzo

, Mh Kulke, M. Shah, Ww De Herder, S. Turri, J. Capdevila, C. Massacesi and other authors.

This paper is available in a repository.

Full text: Download

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload

Abstract

This was a two-stage, phase II trial of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor BEZ235 in patients with everolimus-resistant pancreatic neuroendocrine tumours (pNETs) (NCT01658436).